Variable TGF-β1 signaling activity in ILD patient tissues at different disease stages has not previously been reported and suggests that TGF-β1 may have a different effect in patients with mild disease as compared with late- or end-stage disease. The gene discussed is TGFB1; the disease is interstitial lung disease.